首页 / 院系成果 / 成果详情页

Targeting histone deacetylases for cancer therapy: Trends and challenges 期刊论文 WOS高被引论文

编号：

6B7BA0BD031D73F7B2A0A8C34192BC1C
作者：

Liang, Tao(梁涛)#^[1,5,6]Wang, Fengli^[2,3];Elhassan, Reham M.^[5,6];Cheng, Yongmei^[1];Tang, Xiaolei(唐晓磊)^[2,3,4]Chen, Wengang(陈文刚)*^[1]Fang, Hao(方浩)*^[5,6]Hou, Xuben*^[5,6]
语种：

英文
期刊：

ACTA PHARMACEUTICA SINICA B ISSN：2211-3835 2023 年 13 卷 6 期 (2425 - 2463) ; JUN
收录：
关键词：

HDACs Oncogenesis Selective inhibitor Combination therapy Multitarget agent PROTAC
摘要：

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and pro-gression. As promising anticancer targets, HDACs have gained a great deal of research interests and two de-cades of effort has led to the approval of five HDAC inhibitors (HDACis). However, currently traditional HDACis, although effective in approved indications, exhibit severe off-target toxicities and low sensitivities against solid tumors, which have urged the development of next-generation of HDACi. This review investi-gates the biological functions of HDACs, the roles of HDACs in oncogenesis, the structural features of different HDAC isoforms, isoform-selective inhibitors, combination therapies, multitarget agents and HDAC PROTACs. We hope these data could inspire readers with new ideas to develop novel HDACi with good iso-form selectivity, efficient anticancer effect, attenuated adverse effect and reduced drug resistance.& COPY; 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
推荐引用方式
GB/T 7714：

Liang Tao,Wang Fengli,Elhassan Reham M., et al. Targeting histone deacetylases for cancer therapy: Trends and challenges [J].ACTA PHARMACEUTICA SINICA B,2023,13(6):2425-2463.
APA：

Liang Tao,Wang Fengli,Elhassan Reham M.,Cheng Yongmei,&Hou Xuben.(2023).Targeting histone deacetylases for cancer therapy: Trends and challenges .ACTA PHARMACEUTICA SINICA B,13(6):2425-2463.
MLA：

Liang Tao, et al. "Targeting histone deacetylases for cancer therapy: Trends and challenges" .ACTA PHARMACEUTICA SINICA B 13,6(2023):2425-2463.
入库时间：

7/26/2023 10:01:17 PM
更新时间：

7/26/2023 10:01:17 PM

浏览次数：23  下载次数：0

分享到：

浏览次数：23

下载次数：0

打印次数：0